CUPR (32) LFWD (46) RGNT (44) HSCS (43) ⌘ Pro Terminal →

CollPlant Biotechnologies Ltd (CLGN) — RQD Stock Rating Cockpit

$4.40 +11.39% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

CollPlant Biotechnologies Ltd (CLGN) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $12.7M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-3.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLGN)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMBULLISH MOMENTUM

56.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

5 / 99-Pt Accounting

52-WEEK LASER RANGE9% OF RANGE

L: $3$4.40H: $23

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: C-RQD 24 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on CLGN

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 64.8% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (55)

Altman-Z 4.20 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (52)

18/40 institutional & smart-money positioning score with 13/20 macro alignment.

Bull Case: Why Buyers Like CLGN

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLGN)

✓Walkthrough of CLGN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CLGN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +14.88%▲ ASCENDING CHANNEL

2026-10-30O $4.20H $4.60L $4.10C $4.40VOL 44.2K

RES: $12.43SUP: $3.53SMA50: $3.69SMA200: $5.11

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLGN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLGN Butterfly Map → + Track CLGN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CLGN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLGN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CLGN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLGN)

Health Care Rank #353 of 1016 ⚔️ CUPR vs CLGN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLGN vs. CUPR, LFWD, RGNT, HSCS)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, CollPlant Biotechnologies Ltd (CLGN) ranks #353 by composite RQD confidence (50/100, grade D) and #873 by equity capitalization ($12.7M). Within this direct 5-issuer industry benchmark cohort, CLGN leads on earnings valuation at N/A trailing P/E, while CLGN leads on capital efficiency and profitability with -35.0% ROIC and 64.8% gross margin. CLGN currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CLGN ACTIVE CollPlant Biotechnologies Ltd	D	50/100	—	64.8%	-35.0%	+11.39%	$12.7M	Benchmark Subject
CUPR Cuprina Holdings (Cayman) Limited (Class A)	E	32/100	—	-1.3%	-35.0%	-1.07%	$14.1M	/cupr-vs-clgn →
LFWD Lifeward Ltd.	D	46/100	—	96.0%	-35.0%	+2.78%	$16.7M	/lfwd-vs-clgn →
RGNT Regentis Biomaterials Ltd.	D	44/100	—	—	-35.0%	+10.57%	$9.6M	/rgnt-vs-clgn →
HSCS HeartSciences Inc.	D-	43/100	—	59.1%	-35.0%	+7.12%	$17.5M	/hscs-vs-clgn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001631487

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CollPlant Biotechnologies Ltd (CLGN) reported GAAP revenue of $2.4M (+360.4% vs. FY2024 revenue of $515.0K , and -78.4% cumulative change since FY2023) , GAAP net income of -$11.5M, operating cash flow of -$9.4M, and free cash flow of -$9.4M (+35.2% YoY). On the balance sheet, CLGN closed FY2025 with $10.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.4M	-$11.5M	-$9.4M	-$9.4M	$10.8M	—
FY2024 (FY)	2024-12-31	$515.0K	-$16.6M	-$14.1M	-$14.6M	$18.7M	—
FY2023 (FY)	2023-12-31	$11.0M	-$7.0M	-$2.8M	-$2.8M	—	—

3. CLGN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLGN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, CollPlant Biotechnologies Ltd (NASDAQ: CLGN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $4.40 (+11.39% 1D, market cap $12.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CLGN ranks #353 in composite RQD confidence.

How does CLGN compare to CUPR and LFWD in the Health Care sector?

Within the Health Care sector (Industrial Specialties), CLGN carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 64.8%, and ROIC of -35.0%. By comparison, CUPR (Cuprina Holdings (Cayman) Limited (Class A)) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $14.1M) and LFWD (Lifeward Ltd.) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $16.7M). Among the 5-stock peer group, CLGN leads on earnings multiple (N/A) while CLGN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLGN?

Per CLGN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001631487), CollPlant Biotechnologies Ltd generated $2.4M in revenue (+360.4% YoY), -$11.5M in net income, and -$9.4M in free cash flow against $10.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLGN trading relative to its 50-day, 200-day, and 52-week technical levels?

CLGN last traded at $4.40 (+11.39% on volume of 167,112 shares), positioning the stock +19.24% above its 50-day simple moving average ($3.69) and -13.89% below its 200-day simple moving average ($5.11). Across its 52-week range of $2.64 to $22.90, CLGN sits at the 8.7% percentile with a 14-day RSI of 56.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($3.85 to $4.95).

CLGN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CLGN stock right now?

CollPlant Biotechnologies Ltd (CLGN) currently earns a Roarable Rating of D (Sell — SELL) with 50/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is CLGN's 12-month price target and RQD AI Jury consensus?

CLGN's 12-month base price target is $4.24 (range $3.31 to $24.04), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CLGN RQD Cockpit CLGN 12M Forecast CLGN Earnings & Move CLGN Dividends & DRIP CLGN Insiders & 13F CLGN Whale Options CLGN Profit Sankey CLGN News & Why